|
gptkbp:instance_of
|
gptkb:virus
|
|
gptkbp:antiviral_drugs
|
gptkb:valacyclovir
gptkb:acyclovir
gptkb:famciclovir
|
|
gptkbp:cause
|
chickenpox
shingles
|
|
gptkbp:character_traits
|
one serotype
|
|
gptkbp:community_health
|
herd immunity
outbreaks
|
|
gptkbp:complication
|
gptkb:disease
gptkb:pneumonia
gptkb:multiple_sclerosis
thrombocytopenia
|
|
gptkbp:contraindication
|
pregnancy
immunocompromised individuals
severe allergic reaction
|
|
gptkbp:diagnosis
|
clinical examination
serological tests
PCR testing
|
|
gptkbp:discovery_year
|
gptkb:1954
|
|
gptkbp:diseases
|
dorsal root ganglia
|
|
gptkbp:first_identified_by
|
gptkb:Thomas_Weller
|
|
gptkbp:has_been_restored
|
shingles
|
|
gptkbp:hosts
|
gptkb:humans
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
VZV
|
|
gptkbp:incubation_period
|
10 to 21 days
|
|
gptkbp:is_a
|
gptkb:herpesvirus
|
|
gptkbp:is_recognized_as
|
human patients
|
|
gptkbp:is_vulnerable_to
|
gptkb:varicella_vaccine
over 90%
fever
two doses
subcutaneous injection
live attenuated vaccine
zoster vaccine
mild rash
tenderness at injection site
|
|
gptkbp:nutritional_value
|
gptkb:Herpesviridae
|
|
gptkbp:prevention
|
vaccination
|
|
gptkbp:related_to
|
gptkb:herpes_simplex_virus
|
|
gptkbp:risk_factor
|
stress
certain medications
immunocompromised state
age over 50
|
|
gptkbp:seed_dispersal
|
double-stranded DNA
|
|
gptkbp:symptoms
|
fever
rash
1 to 2 weeks
itching
|
|
gptkbp:transmission
|
direct contact
airborne droplets
|
|
gptkbp:treatment
|
gptkb:immunotherapy
symptomatic relief
|
|
gptkbp:treatment_timing
|
early intervention recommended
|
|
gptkbp:vaccine_age_recommendation
|
12 months and older
|
|
gptkbp:virus_genus
|
gptkb:Varicellovirus
|
|
gptkbp:bfsParent
|
gptkb:Herpesviridae
gptkb:herpesviridae_family
|
|
gptkbp:bfsLayer
|
6
|